Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 17/20 | 0.37 |
| ▸ | CDK1 | P06493 | 17/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 17/20 | 0.37 |
| ▸ | GSK3B | P49841 | 15/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.37 |
| ▸ | GSK3A | P49840 | 10/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380377 | 1.00 | CCNB2 (0.37) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL29915242 | 0.75 | — | — | |
| SCHEMBL2927541 | 0.68 | — | — | |
| SCHEMBL29486398 | 0.68 | DAO (0.56) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29486393 | 0.68 | DAO (0.56) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL747250 | 0.68 | DAO (0.56) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL167012 | 0.68 | ATAD2 (0.56) | CDK1 | |
| SCHEMBL167394 | 0.68 | MAPK1 (0.46) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL29623547 | 0.68 | MAPK1 (0.46) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL29819493 | 0.67 | FGFR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025240673-A1 | CANCER TREATMENT USING AKT INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2025-11-20 | — | — | WO | claimed |
| CN-120202002-A | Pharmaceutical composition for treating cancer | 微境生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-118047779-B | Dihydropteridinone derivatives containing benzobisheteroaryl and use thereof | 沈阳药科大学 | 2025-02-11 | — | — | CN | claimed |
| WO-2025029980-A1 | INHIBITION OF HYPOXIA SIGNALING PATHWAY BY PLK1 INHIBITOR | CARDIFF ONCOLOGY, INC. (US) | 2025-02-06 | — | — | WO | claimed |
| US-20250017933-A1 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. | 2025-01-16 | — | — | US | claimed |
| CN-119241548-A | Dihydropteridinone derivatives containing fused benzene rings and use thereof | 沈阳药科大学 | 2025-01-03 | — | — | CN | claimed |
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. | 2024-06-20 | — | — | US | claimed |
| WO-2024114730-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER | 微境生物医药科技(上海)有限公司 | 2024-06-06 | — | — | WO | claimed |
| CN-118047779-A | Dihydropteridinone derivatives containing benzobisheteroaryl and use thereof | 沈阳药科大学 | 2024-05-17 | — | — | CN | claimed |
| CN-117794523-A | Cancer treatment using PARP inhibitors and PLK1 inhibitors | 凯帝夫肿瘤科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | claimed |
| WO-2008130921-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DEPRESSION AND ANXIETY | MODGENE, LLC (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| EP-1778238-A1 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-02 | — | — | EP | claimed |
| EP-1778668-A2 | METHOD FOR THE PRODUCTION OF DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-02 | — | — | EP | claimed |
| WO-2006018221-A1 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| WO-2006018220-A2 | METHOD FOR THE PRODUCTION OF DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| US-20040204420-A1 | For therapy of diseases and disorders associated with unwanted or aberrant gene expression | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-14 | — | — | US | claimed |
| WO-2004042002-A2 | COMPOUNDS FOR MODULATING RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-05-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017933-A1 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | PLK1, KDM1B, EZH2 | CCNB2 237/4885CDK1 43/4885CCNB1 219/4885 |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | CCNB2 1257/4885CDK1 1331/4885CCNB1 717/4885 |
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK2, CHEK1 | CCNB2 163/4885CDK1 28/4885CCNB1 145/4885 |
| US-20040204420-A1 | For therapy of diseases and disorders associated with unwanted or aberrant gene expression | SNRPE, L3MBTL1, ATF4 | CCNB2 3411/4885CDK1 3469/4885CCNB1 3603/4885 |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | CCNB2 1257/4885CDK1 1331/4885CCNB1 717/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | CCNB2 917/4885CDK1 2177/4885CCNB1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.